Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Hayley Cowan was sentenced to four months and banned from keeping animals for life after killing Staffordshire Bull Terrier Beau.
The High Court has ruled the prison segregation of two terrorists was unlawful although it rejected claims their human rights were abused.
Michel Platini has formally announced that he intends to stand for the Fifa presidency when Sepp Blatter vacates the position